1-(4-chlorophenyl)-2-(methylamino)ethanol | 40587-06-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-chlorophenyl)-2-(methylamino)ethanol
• 英文别名: N-Methyl-β-hydroxy-4-chloro-phenethylamine；4-Chlor-1-(1-hydroxy-2-methylamino-ethyl)-benzol
• CAS: 40587-06-2
• 化学式: C₉H₁₂ClNO
• 分子量: 185.653
• InChiKey: PRHFCODVVHEZRP-UHFFFAOYSA-N

物化性质

• 沸点：
  308.3±27.0 °C(Predicted)
• 密度：
  1.176±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-chlorophenyl)-2-(methylamino)ethanol 在 溶剂黄146 、 sodium nitrite 作用下， 以 水 为溶剂， 生成 4-Chlor-1-(1-hydroxy-2-methylnitrosamino-ethyl)-benzol
  参考文献：
  名称：

  Synthesis, in Vitro Activity, and Three-Dimensional Quantitative Structure−Activity Relationship of Novel Hydrazine Inhibitors of Human Vascular Adhesion Protein-1

  摘要：

  Vascular adhesion protein-1 (VAP-1) belongs to the semicarbazide-sensitive amine oxidases (SSAOs) that convert amines into aldehydes. SSAOs are distinct from the mammalian monoamine oxidases (MAOs), but their substrate specificities are partly overlapping. VAP-1 has been proposed as a target for anti-inflammatory drug therapy because of its role in leukocyte adhesion to endothelium. Here, we describe the synthesis and in vitro activities of novel series of VAP-1 selective inhibitors. In addition, the molecular dynamics simulations performed for VAP-1 reveal that the movements of Met211, Ser496, and especially Leu469 can enlarge the ligand-binding pocket, allowing larger ligands than those seen in the crystal structures to bind. Combining the data from molecular dynamics simulations, docking, and in vitro measurements, the three-dimensional quantitative structure-activity relationship (3D QSAR) models for VAP-1 (q(LOO)(2): 0.636; r(2:) 0.828) and MAOs (q(LOO)(2): 0.749, r(2): 0.840) were built and employed in the development of selective VAP-1 inhibitors.

  DOI：

  10.1021/jm100337z
• 作为产物：
  描述：

  2'-溴-4-氯苯乙酮 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 1-(4-chlorophenyl)-2-(methylamino)ethanol
  参考文献：
  名称：

  Amschler; Schultz, Arzneimittel-Forschung/Drug Research, 1972, vol. 22, # 12, p. 2095 - 2096

  摘要：

  DOI：

文献信息

• Asymmetric Hydrogenation of α-Primary and Secondary Amino Ketones: Efficient Asymmetric Syntheses of (−)-Arbutamine and (−)-Denopamine
  作者：Gao Shang、Duan Liu、Scott E. Allen、Qin Yang、Xumu Zhang

  DOI：10.1002/chem.200700594

  日期：2007.9.17

  Two beta-receptor agonists (-)-denopamine and (-)-arbutamine were prepared in good yields and enantioselectivities by asymmetric hydrogenation of unprotected amino ketones for the first time by using Rh catalysts bearing electron-donating phosphine ligands. A series of alpha-primary and secondary amino ketones were synthesized and hydrogenated to produce various 1,2-amino alcohols in good yields and

  通过使用带有给电子膦配体的Rh催化剂进行不保护的氨基酮的不对称氢化，以高收率和对映选择性制备了两种β受体激动剂（-）-地巴胺和（-）-arbutamine。合成了一系列的α-伯氨基和仲氨基酮并进行氢化，以高收率和良好的对映选择性生产出各种1,2-氨基醇。这种Rh电子给体的膦催化的不对称氢化反应代表了手性氨基醇不对称合成的最有希望和最方便的方法之一。
• Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases
  申请人：MACSÁRI István

  公开号：US20120122843A1

  公开（公告）日：2012-05-17

  The present invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds, processes for making said compounds, and their use as medicaments for treatment and/or prevention of Aβ-related diseases.

  本发明涉及式(I)的新化合物及其药用盐，包括含有该化合物的药物组合物，制备该化合物的方法，以及它们作为治疗和/或预防Aβ相关疾病的药物的用途。
• Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof
  申请人：Research Institute of Material Medica, Chinese Academy of Medical Sciences;

  公开号：US20040029951A1

  公开（公告）日：2004-02-12

  The invention relates to sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones compounds having formula (I) 1 wherein R 1 is selected from the group consisting of 4-methylsulfonyl, 4-aminosulfonyl, hydrogen, 2-, 3-, or 4-halogen, C 1 -C 6 -alkyl, cyclopentyl, cyclohexyl, C 1 -C 4 -alkoxy, hydroxy, cyano, nitro, amino or trifluoromethyl; R 2 is selected from the group consisting of 4-methylsulfonyl, 4-aminosulfonyl, hydrogen, 2-, 3-, or 4-halogen, C1-C6-alkyl, cyclopentyl, cyclohexyl, C 1 -C 4 -alkoxy, hydroxy, cyano, nitro, amino or trifluoromethyl; and R 3 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, c-propyl, n-butyl, isobutyl; provided that when R 1 is a methylsulfonyl or aminosulfonyl group, R 2 is any group as defined above except a methylsulfonyl or aminosulfonyl group; and when R 2 is a methylsulfonyl or aminosulfonyl group, R 1 is any group as defined above except a methylsulfonyl or aminosulfonyl group, also to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the medical use of such compounds in the treatment of diseases relating to the inhibition of cyclooxygenase-2 (COX-2).

  该发明涉及具有以下结构的磺酰基含有的3,4-二芳基-3-吡咯烯-2-酮化合物，其化学式为（I）： 其中R1选自以下组：4-甲基磺酰基，4-氨基磺酰基，氢，2-，3-或4-卤素，C1-C6-烷基，环戊基，环己基，C1-C4-烷氧基，羟基，氰基，硝基，氨基或三氟甲基；R2选自以下组：4-甲基磺酰基，4-氨基磺酰基，氢，2-，3-或4-卤素，C1-C6-烷基，环戊基，环己基，C1-C4-烷氧基，羟基，氰基，硝基，氨基或三氟甲基；R3选自以下组：氢，甲基，乙基，正丙基，异丙基，仲丙基，正丁基，异丁基；但当R1为甲基磺酰基或氨基磺酰基时，R2为上述定义之外的任何基团；当R2为甲基磺酰基或氨基磺酰基时，R1为上述定义之外的任何基团。同时，该发明还涉及制备这类化合物的方法，含有这类化合物的药物组合物，以及这类化合物在治疗与环氧合酶-2（COX-2）抑制相关的疾病中的医学用途。
• Synthesis of chiral oxazolidinone derivatives through lipase-catalyzed kinetic resolution
  作者：Yan Zhang、Yang Zhang、Yansong Ren、Olof Ramström

  DOI：10.1016/j.molcatb.2015.08.004

  日期：2015.12

  The synthesis of enantioenriched oxazolidinone derivatives through lipase-catalyzed kinetic resolution is described. The synthesis comprised a two-step, cascade acylation in one pot, resulting in a range of oxazolidinone derivatives in good yields and excellent enantiopurities.

  描述了通过脂肪酶催化的动力学拆分合成对映体富集的恶唑烷酮衍生物。该合成在一锅中包括两步，级联酰化反应，从而产生了一系列具有良好收率和出色对映纯度的恶唑烷酮衍生物。
• 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS
  申请人：——

  公开号：US20040259907A1

  公开（公告）日：2004-12-23

  The invention provides a compound of formula I: 1 wherein G, R 2 , R 3 , and R 4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of treating a herpesvirus infection using such compounds or salts.

  该发明提供了公式I的化合物：1其中G、R2、R3和R4具有规范中定义的任何值，或其药学上可接受的盐，以及用于制备这种化合物或盐的过程和中间体，以及使用这种化合物或盐治疗疱疹病毒感染的方法。